The policy is to promote GeneTech’s NIPT (non-invasive prenatal testing) business responsibly, with emphasis on appropriate procedures in line with professional society guidelines and consideration of its social impact. Following the transfer of all shares, it was removed from the Group’s ongoing strategic themes.